AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03149198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mat Pilates exercises
Description: The exercise program based on the pilates method will be performed on the ground in the group room of the FACISA / UFRN Physiotherapy School Clinic in Santa Cruz. The room has ample space and air conditioning for better patient accommodation. The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by a physical therapy student along with the research coordinator. A total of 10 exercises will be performed.
Study NCT03149198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic aerobic exercises
Description: The aerobic exercise program will be held in the therapeutic pool of the Physiotherapy School Clinic of FACISA / UFRN in Santa Cruz. The pool is heated and provides better effects to the proposed treatment.~The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by another physical therapy student along with the research coordinator.
Study NCT02305056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C13 N15 Valine
Description: C13 N15 Valine administration
Study NCT04534049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Flexibility Training (FT)
Study NCT04446767 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: polarized light
Description: bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks
Study NCT00016016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00016016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT04446767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Care
Description: Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
Study NCT00844415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: 2.14 mg/kg BID to a max 150 mg BID
Study NCT03580525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine saline infusion 0.00mcg/kg/s
Description: saline 0.00mcg/kg/s
Study NCT03580525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine infusion 0.24mcg/kg/s
Description: nicotine 0.24mcg/kg/s
Study NCT03580525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine infusion 0.096mcg/kg/s
Description: nicotine 0.096mcg/kg/s
Study NCT03580525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine infusion 0.048 mcg/kg/s
Description: nicotine 0.048mcg/kg/s
Study NCT03580525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine infusion 0.024mcg/kg/s
Description: nicotine 0.024mcg/kg/s
Study NCT00016016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00016016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00016016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory procedure
Description: Correlative studies
Study NCT00003170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glutamine
Study NCT00003170 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03713151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dividat FIT
Description: The study intervention is a blended therapy approach of face-to-face physiotherapy sessions with an interactive tablet-based home exercise program.
Study NCT02003768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 80 patients are randomly allocated into two groups: In TIVA group, propofol based total intravenous anesthesia is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
Study NCT02003768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: 80 patients are randomly allocated into two groups : In Des group, inhalation anesthesia using desflurane is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
Study NCT02597972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fracture repair
Study NCT02597972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fracture repair with joint replacement
Study NCT03904004 — intervention group
Intervention type: PROCEDURE
Intervention: Peroral endoscopic myotomy
Description: Endoscopic myotomy after performing a tunnel to reach the muscular layer through a mucosal incision
Study NCT03904004 — intervention group
Intervention type: PROCEDURE
Intervention: Neumatic dilatation
Description: Inflation of a ballon of specific diameter in the gastro-oesophageal junction
Study NCT03904004 — intervention group
Intervention type: PROCEDURE
Intervention: Botulinum toxin injection
Description: Injection of botulinic toxin to inhibit the contraction of the gastro-oesophageal junction muscular layer
Study NCT03904004 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Heller Myotomy
Description: Five or six small incisions are made in the abdominal wall and laparoscopic instruments are inserted. The myotomy is a lengthwise cut along the oesophagus, starting above the lower oesophageal sphincter (LOS) and extending down onto the stomach a little way. The oesophagus is made of several layers, and the myotomy only cuts through the outside muscle layers which are squeezing it shut, leaving the inner mucosal layer intact.
Study NCT00832689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan and Gemcitabine
Study NCT04063397 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Serial echocardiograms will be done on all patients pre-delivery, and at 3-6 months
Study NCT04063397 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Serial blood draws at same time points as echocardiograms for biomarker levels
Study NCT00576147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrascanner
Description: The main Near-Infrared spectroscopy (NIRS) head measurement
Study NCT04432168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetoscopic Laser Surgery
Description: Fetoscopic Photocoagulation of the connecting vascular anastomoses on the surface of the placenta.
Study NCT04432168 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Treatment
Description: In the control group, the choices of treatment include expectant management, intrauterine transfusion (IUT) (with or without partial exchange transfusion (PET)) or preterm delivery, depending on the judgment of the fetal surgeon with regard to the gestational age and state of the disease.~* Expectant management will consist of close monitoring with ultrasound including Doppler measurements of the middle cerebral artery peak systolic velocity (MCA-PSV), at least every week.~* IUT: the intrauterine infusion of red blood cells into the circulation of the donor twin treat anemia.~* PET: the intrauterine infusion of saline into the circulation of the recipient twin to treat polycythemia.~* Preterm delivery: Induction of labor or cesarean section before 36 weeks of gestation.
Study NCT06409507 — intervention group
Intervention type: GENETIC
Intervention: FKBP12 expression
Description: The expressions of FKBP12 were determined by immunohistochemistry (IHC) , and the immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels, and IRS (8-12) represented high expression levels.
Study NCT04941976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% benzydamine hydrochloride spray oromucosal solution
Description: Single application of 0.3% benzydamine hydrochloride spray oromucosal solution. Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution.
Study NCT04941976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single 3 mg lozenge of benzydamine hydrochloride (mint flavour)
Description: Single 3 mg lozenge of benzydamine hydrochloride (mint flavour). Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution.
Study NCT02159768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airtraq visualization
Description: Larynx visualization with Airtraq and attached handphone
Study NCT00462267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enriched lifestyle intervention
Description: Multi-component lifestyle intervention
Study NCT00994760 — intervention group
Intervention type: DRUG
Intervention: Instanyl (Intranasal Fentanyl)
Description: This was an observational study. Therefore, the physician decided about dosage according to individual needs.
Study NCT02407691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care 101 plus mental health
Description: A facility-based stepped care intervention combining depression case detection by non-physician clinicians with group counselling intervention delivered by lay-health workers.
Study NCT02407691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Primary Care 101
Description: Standard Primary Care 101 guideline with standard training
Study NCT02343952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.
Study NCT03398824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin HCl
Description: Receive metformin HCl
Study NCT02096471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Study NCT05230290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KD6001 Injection
Description: Solution for intravenous injection
Study NCT04864327 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief smoking cessation advise
Description: The tobacco cessation protocol consisted of performing a routine assessment (asking) of cigarette use; providing advice on the importance of quitting; performing an assessment of the tobacco user's readiness to quit; assisting in setting a quit date; and making arrangements for follow-up visits. This protocol is popularly known as the 5A's strategy (The first 3A's should be delivered to all smokers regardless of their willingness to quit). Tobacco users were identified by staff nurses. Clinicians provided brief advice on quitting, and the researcher assessed the patient's dependence and readiness to quit. Patients who were not ready to quit were motivated to consider quitting, whereas those who were ready to quit were referred to practitioners who could assist them and follow them in the tobacco cessation clinic
Study NCT00720720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plant sterol enriched margarine
Description: Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.
Study NCT00720720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: plant sterol enriched margarine
Description: Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.
Study NCT00720720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo margarine
Study NCT03170492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RehaCom Computerized Cognitive Training for 480 minutes
Description: Student OT doctoral researchers will guide the subject when participating in the RehaCom program. RehaCom is computer hardware and software designed for assisted cognitive rehabilitation. The program is designed to target specific aspects of attention, concentration, memory, perception, and problem-solving. As the training goes on, the tasks will become easier or harder depending on the subject's performance. The first session will begin with a screening module with an example and a practice session to make sure the client understands the task. After screening, the results page shows the subject's performance compared with age-matched norms. This gives a helpful indication as to the severity of the deficit and advises the researcher on the particular training module to be used. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
Study NCT03170492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pencil-and-Paper Cognitive Training for 480 minutes
Description: Student OT doctoral researchers will engage the subject in various pen-and-paper exercises designed to improve cognitive functions: attention and concentration, memory, language, calculation, and orientation. These could include, but are not limited to: word puzzles, calculation or number puzzles, and map reading. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
Study NCT05478967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVA injection before vitrectomy
Description: Patients in IVA group received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)
Study NCT01660646 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral: community sensitization
Description: Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
Study NCT06107790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS022
Description: 8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg
Study NCT06107790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg
Study NCT06107790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Bitartrate
Description: Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). 3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~Second section:9 treatment cycles, 3 weeks/cycle, 27 weeks. Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). The investigator may decide whether to continue treatment with vinorelbine at his discretion.~3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.
Study NCT06107790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine Bitartrate
Description: Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). 3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~Second section:9 treatment cycles, 3 weeks/cycle, 27 weeks. Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). The investigator may decide whether to continue treatment with vinorelbine at his discretion.~3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.
Study NCT00392951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)
Study NCT03215745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delirium prevention program
Description: Delirium prevention program Placard with the names of the care team and the calendar days; cognitively stimulating activities three times a day. Pictures, radio, robe. Visual aids large print books, with daily reinforcement of use Maintain adequate lighting opening blinds and curtains during the day, and darken their environment at night. Dissipation wax and special techniques of communication, with daily reinforcement of these adaptations. Go to the patient by name and tone of voice appropriate. Always listen. Use simple and clear language, face-to-face. Avoid excessive familiarity and childish. Promote family involvement in self-care and caregivers and the reorientation of the patient, contact with extended family during the stay.
Study NCT00636155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cenersen sodium
Description: 2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4
Study NCT00636155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on day 2
Study NCT00636155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m2 on days 2, 3, and 4
Study NCT00636155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 on days 2, 3, and 4
Study NCT04383964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distraction Osteogenesis for Reconstruction of Ramus-Condyle
Description: transport distraction osteogenesis in restoring the deficient condyle/ramus unit of patients with TMJ ankylosis to correct the resultant deformity either unilaterally or bilaterally.
Study NCT01446991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: 240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
Study NCT01446991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: 240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
Study NCT00782106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase + immune globulin intravenous
Description: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
Study NCT00782106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase + immune globulin intravenous
Description: 1. IV infusion of IGIV, 10% to determine pharmacokinetics~2. Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
Study NCT02852291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents Make the Difference
Description: 10 parent training sessions delivered to groups of caregivers
Study NCT02852291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents Make the Difference Plus
Description: 10 parent training sessions delivered to groups of caregivers, with 3 home visits
Study NCT00551967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip replacement
Description: Surgical implantation of hip replacement components for the treatment of osteoarthritis
Study NCT03828565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ScvO2 Perioperative continue monitoring
Description: ScvO2 Perioperative continue monitoring with PreSep® system. If SvcO2 is less than 65% or decreases by more than 10% of its base value, the other parameters affecting ScvO2 (BIS (40-60% objective), Hb (objective> 8g / dL), SaO2 (objective> 94%)) are evaluated. If, after correcting for these parameters, the ScvO2 is not corrected, the preload-dependence parameters are evaluated (variation of the pulsed pressure) to guide the vascular filling: VF of 250 mL of crystalloids if PPV> 13%, norepinephrine if PPV\<9%, reassess if PPV between 9 and 13%.~If VF or norepinephrine does not correct ScvO2 (> 65%), a measurement of arterial lactate is performed. If lactatemia is> 2 mmol / L, a positive inotrop is introduced after ETO if possible. If lactatemia is \<2 mmol / L, a return to the evaluation phase of the parameters influencing ScvO2 is necessary.
Study NCT02907411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadrivas Therapy
Description: Quadrivas therapy will be applied to subjects. Quadrivas therapy is a intensive massage therapy for different tissues. Subjects will receive 12 treatments. The first lasting 2.5 hours and the remaining 11 lasting 1.5 hours.
Study NCT02669446 — intervention group
Intervention type: DEVICE
Intervention: Medical devices
Study NCT02669446 — intervention group
Intervention type: DEVICE
Intervention: traditional household remedy